Disclosure of potential conflict of interest: A. E. Dixon’s institution has received funding from the National Institutes of Health and Merck; she has received consultancy fees from Roche and has received grants or has grants pending from Pfizer and receives royalties from Springer. M. Castro’s institution has received funding from the National Institutes of Health (NIH) and has received grants or has grants pending from Boston Scientific, Amgen, Ception, Cephalon, Teva, Genentech, Medimmune, Merck, Novartis, GlaxoSmithKline, Sanofi Aventis, Vectura, Next Bio, and KalosBios; he has received consultancy fees from Asthmatx/Boston Scientific, Genentech, IPS/Holaira, and Neostem; has received payment for delivering lectures from GlaxoSmithKline, Genentech, Boston Scientific, Boehringer Ingelheim, and Teva; receives royalties from Elsevier; and has stock/stock options from Sparo. R. I. Cohen’s institution has received funding from the American Lung Association– Asthma Clinical Research Center. C. G. Irvin has received consultancy fees from TEVA and has received grants or has grants pending from Hydra Bioscience and receives royalties from UpToDate. S. P. Peters has received consultancy fees from the Coordination Center at Johns Hopkins, AstraZeneca, Aerocrine, Airsonett AB, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Ono Pharmaceuticals, Pfizer, Sunovion, Targacept, TEVA, Pharmaceutical Product Development, LLC, and Quintiles; has received payment for delivering lectures from Integrity CE; and receives royalties from UpToDate. R. A. Wise’s institution has received funding from Merck, as well as consultancy fees from AstraZeneca, Merck, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Pfizer, Mylan, Roche, Janssen, Pulmonx, Spiration, Intermune, Medimmune, Sunovion, and Forest; he has received support for travel and other meeting-related expenses from Forest. The rest of the authors declare that they have no conflicts of interest.